Description
TRANXEMIC ACID
Tranxemic acid is a synthetic derivative of the amino acid lysine. It is an antifibrinolytic that competitively inhibits the activation of plasminogen to plasmin, by binding to specific sites of both plasminogen and plasmin, a molecule responsible for the degradation of fibrin. Fibrin is a protein that forms the framework of blood clots. It has roughly eight times the antifibrinolytic activity of an older analogue, ε -aminocaproic acid.
MEFENAMIC ACID
Mefenamic acid is a non-steroidal anti-inflammatory drug used to treat pain, including menstrual pain.
However it is thought to be related to the inhibition of prostaglandin synthesis. Since hepatic metabolism plays a significant role in mefenamic acid elimination. Kidney deficiency may also cause accumulation of the drug and its metabolites in the excretory system.
PHARMACOLOGY:
Tranexamic acid (AMCA) is a potent antifibrinolytic drug occurring in two isomeric forms; the antifibrinolytic potency resides in the transisomeric form. The main action of AMCA is blocking of the lysine-binding sites of the plasminogen molecule, which are of importance for the binding to fibrin. This prevents activation of plasminogen by plasminogen activator also absorbed to fibrin. AMCA can be administered perorally or intravenously and is excreted into the urine. It enters tissues and fluids in various concentrations and crosses the placenta. There is no evidence of a thrombogenic effect of AMCA, but in accordance with its action, it prolongs dissolution of fibrin deposits already formed. AMCA is a drug of high clinical value for the treatment of bleedings due to both systemic and local fibrinolysis Ponstel (mefenamic acid) is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models.
PHARMACODYNAMICS:
This is a non-steroidal anti-inflammatory drug (NSAID) that exhibits anti-inflammatory, analgesic, and antipyretic activities in animal models. The mechanism of action of mefenamic acid, like that of other NSAIDs, is not completely understood but may be related to prostaglandin synthetase inhibition
PHARMACOKINETICS
MEFENAMIC ACID:
- Bioavailability: – 90%
- Excretion: – Renal and fecal
- Half-Life; – 2 hours
- Metabolism: – Hepatic (CYP2C9)
- Protein binding: – 90%
TRANEXAMIC ACID:
- Bioavailability: – 34%
- Excretion: – Urinary
- Half-Life: – 3.1 hours
- Metabolism: – Hepatic (CYP2C9)
- Protein binding: – 90%
INDICATIONS
- Mild to moderate pain
- Rheumatoid arthritis
- Dental pain
- Postoperative pain
- Dysmenorrhoea
- Osteoarthritis
- Menorrhagia
